# 2025-08143: FDA Ranks DNA Cancer Detector as Safe Tool

2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08143
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08143
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19638
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

FDA Ranks DNA Cancer Detector as Safe Tool

## Summary

The FDA is officially putting the DNA-based test that checks for tiny amounts of leftover cancer cells in blood cancers into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while making it simpler for companies to get it to patients faster. The new rules started on May 9, 2025, and could speed up access to this important test without extra costs.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the DNA-based test to measure minimal residual disease in hematological malignancies into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the DNA-based test to measure minimal residual disease in hematological malignancies classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- MRD Test Moved to Class II: benefit, high. The FDA officially classified the DNA-based test to measure minimal residual disease (MRD) in hematological malignancies as Class II (special controls), effective May 9, 2025, with the classification applicable on September 28, 2018. As a Class II device, it is subject to premarket notification und…
- Enables Faster Market Entry for Future Tests: benefit, medium. FDA stated that when a device is classified into Class II via the De Novo process, that device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application. This change was…
- Required Test Validation and Reporting Standards: benefit, medium. The final order establishes special controls requiring detailed design verification and validation studies, labeling that lists the clinical hematopoietic malignancy, specimen type, and specific DNA regions detected, and requires the device output to include an estimated MRD frequency plus an uncer…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08143 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08143/medical-devices-immunology-and-microbiology-devices-classification-of-the-dna-based-test-to-measure)
- [2025-08143 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08143.pdf)

## Related
- [Previous: 2025-08137, New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Appro…](https://policyrisk.com/federal-register/2025-08137)
- [Next: 2025-08144, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2025-08144)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08143 (as of 2026-10-16).
